Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 785M 687M 633M 586M 1.11B 74.95B 1.13B 7.59B 2.97B 36.81B 2.95B 2.88B 127B P/E 2026 *
4.04x
P/E 2027 * 3.86x
Enterprise Value 785M 687M 633M 586M 1.11B 74.95B 1.13B 7.59B 2.97B 36.81B 2.95B 2.88B 127B EV / Sales 2026 *
1.71x
EV / Sales 2027 * 1.64x
Free-Float
96.84%
Yield 2026 *
-
Yield 2027 * -
1 day-1.99%
1 week+7.62%
Current month+10.69%
1 month+44.72%
3 months+29.44%
6 months+14.78%
Current year+38.28%
1 week 4.27
Extreme 4.27
4.88
1 month 3.2
Extreme 3.2
4.88
Current year 2.95
Extreme 2.95
5.78
1 year 0.67
Extreme 0.6701
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 11/03/2021
Director of Finance/CFO 44 14/05/2026
Chief Tech/Sci/R&D Officer - 31/03/2024
Director TitleAgeSince
Director/Board Member 68 03/06/2021
Chairman 61 31/03/2019
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Director

63,481 0.0386%
06-15Free

Director

63,481 0.0386%
06-15Free

Chairman

85,052 0.0517%
Change 5-day change 1-year change 3-year change Capi.($)
-1.99%+7.62%+479.39%-54.54% 785M
-0.91%-3.44%+49.45%+13.77% 311B
+0.32%-5.36%+25.43%-4.29% 68.98B
-1.57%-0.18%+40.16%+112.50% 9.53B
-0.21%+4.27%+6.96%+1.89% 8.62B
-2.31%-7.50%-13.48%+6.37% 4.26B
+4.55%-4.61%+15.19%+24.63% 3.83B
-2.46%-4.40%-36.65%+24.81% 3.41B
-4.36%+0.80%+48.26%+62.37% 2.93B
+0.28%-6.94%+9.56%-24.42% 2.08B
Average -0.88%-0.89%+62.43%+16.31% 41.56B
Weighted average by Cap. -0.73%-0.39%+43.31%+12.93%

Financials

2026 *2027 *
Net sales 459M 402M 371M 343M 651M 43.86B 662M 4.44B 1.74B 21.54B 1.72B 1.69B 74.6B 478M 418M 386M 357M 678M 45.66B 689M 4.62B 1.81B 22.42B 1.8B 1.76B 77.67B
Net income 188M 165M 152M 140M 267M 17.97B 271M 1.82B 713M 8.82B 707M 691M 30.56B 210M 184M 169M 157M 297M 20.03B 302M 2.03B 795M 9.84B 788M 771M 34.07B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
09/07/26 US$4.665 -2.20% 1,279,465
08/07/26 US$4.770 +6.71% 4,987,325
07/07/26 US$4.470 +2.05% 3,479,056
06/07/26 US$4.380 +1.15% 3,001,622
02/07/26 US$4.330 +5.10% 2,651,198
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.770USD
Average target price
6.100USD
Spread / Average Target
+27.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock